Botulinum toxin type A for Levodopa-induced cervical dyskinesias in Parkinson's disease: unfavorable risk-benefit ratio

Mov Disord. 2011 Apr;26(5):913-4. doi: 10.1002/mds.23522. Epub 2011 Mar 22.
No abstract available

Publication types

  • Clinical Trial
  • Letter
  • Randomized Controlled Trial

MeSH terms

  • Aged
  • Antiparkinson Agents / adverse effects
  • Botulinum Toxins, Type A / therapeutic use*
  • Dyskinesia, Drug-Induced / drug therapy*
  • Dyskinesia, Drug-Induced / etiology
  • Electromyography / methods
  • Female
  • Humans
  • Levodopa / adverse effects
  • Male
  • Neuromuscular Agents / therapeutic use*
  • Parkinson Disease / drug therapy
  • Treatment Outcome

Substances

  • Antiparkinson Agents
  • Neuromuscular Agents
  • Levodopa
  • Botulinum Toxins, Type A